OSE Immunotherapeutics S.A.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- OSE Immunotherapeutics SA (OSE.PA; ORPOF) is a clinical-stage biotechnology company focused on developing first-in-class immunotherapies targeting immune activation and regulation in immuno-oncology and immuno-inflammation. The company offers a diverse pipeline including Tedopi, a neoepitope-based cancer vaccine in Phase III for non-small cell lung cancer and Phase II for pancreatic and ovarian cancers; OSE-279 in Phase I/II for advanced solid tumors and lymphomas; OSE-127, a monoclonal antibody in Phase II for ulcerative colitis and Sjögren’s syndrome; FR104 in Phase I for rheumatoid arthritis; BI 765063 and BI 770371, anti-SIRPα antagonists licensed to Boehringer Ingelheim for solid tumors; OSE-703 and OSE-172 targeting myeloid suppressive cells in the tumor microenvironment; OSE-230, an agonist antibody against ChemR23 for chronic inflammation; CLEC-1 monoclonal antibody antagonists; and BiCKI, a bispecific PD-1 checkpoint inhibitor platform, alongside preclinical platforms in neoepitopes, cis-targeting anti-PD1/cytokines, and mRNA technologies under the HexARN program. Founded in 2012 and headquartered in Nantes, France, with operations in Paris, OSE Immunotherapeutics employs over 65 staff and maintains global partnerships serving pharmaceutical collaborators and clinical trial patients primarily in Europe and the United States. Recent developments include a 2024 strategic partnership with AbbVie potentially worth up to $713 million including a $48 million upfront payment for immunology assets; expansion of its Boehringer Ingelheim collaboration with a €25.3 million one-time payment for anti-SIRPα programs in immuno-oncology and cardiovascular-renal-metabolic diseases, plus a €13.5 million upfront asset acquisition for a cis-targeting anti-PD1/cytokine program; €8.4 million in non-dilutive France 2030 funding for Tedopi’s Phase III trial; and a May 2025 collaboration with Inside Therapeutics and MiNT Laboratory funded by €1.3 million for mRNA nanodrug advancement; alongside a September 2025 strategic partnership with Inserm Transfert and Nantes University.
OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document
OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients
OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting
OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting
OSE Immunotherapeutics Evolves its Leadership Team
OSE Immunotherapeutics to Present at Upcoming Investor Conferences
OSE Immunotherapeutics Announces its 2026 Financial Calendar
OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi®
OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)
OSE Immunotherapeutics SA (ORPOF) Discusses Strategic Plan With Four Opportunities for Value Creation Transcript